$ITGR

Integer to Be Acquired by KKR Affiliates for $127 Per Share in All-Cash Merger

Integer Holdings Corp said it will be acquired in an all-cash merger by Armstrong Parent and Armstrong Bidco, affiliates of KKR. The offer price is $127 per share, with committed equity and debt financing and no financing condition. Closing is subject to regulatory and stockholder approvals, and Integer will become a wholly owned subsidiary.

Original reporting
Published Aug 4, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 11:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integer to Be Acquired by KKR Affiliates for $127 Per Share in All-Cash Merger — source image
Decision brief

The 30-second read

$ITGRBullishHigh
01

Why it matters

For ITGR, the disclosed $127 per share all-cash consideration and lack of a financing condition are the primary trading drivers, with subsequent focus on regulatory and stockholder approvals.

02

Market read

A signed, definitive take-private at a stated cash price is a high-signal event for deal-arbitrage and hedged positioning in the target stock.

03

What to watch

The article does not specify expected closing timeline, regulatory jurisdictions, or any antitrust/approval hurdles, which are key drivers of deal-spread volatility.

Relevance 9/10Novelty 9/10Timing: deal announced today, after-hours filing referenced

Background

Integer entered a definitive merger agreement with KKR affiliates (Armstrong Parent and Armstrong Bidco) for a take-private transaction.

Company-level read

Ticker impact

$ITGRBullishHigh confidence
Context

Integer announced a definitive take-private merger agreement to be acquired for $127 per share in an all-cash deal supported by committed financing.

Expected impact

Expect ITGR to trade with deal-spread behavior, typically supported by the offer price floor and volatility around deal-approval milestones.

Evidence & confidence

The article discloses a signed definitive merger agreement, the per-share cash consideration, and that financing is committed and not subject to a financing condition, which are the key inputs for near-term trading.

Market effects

Could modestly increase attention on acquisition appetite for software/IT services targets, but the article is company-specific.

Primarily US-focused given the target and SEC filing; limited broader regional spillover.

KKR-backed take-private deals can influence global deal-arb sentiment, but no cross-border operational impact is described.

Counterpoint

Even with committed financing, deal completion risk (regulatory or stockholder approvals) can keep the stock below the offer price and widen the spread.

Key entities

  • Integer Holdings Corp

    Target company entering a definitive all-cash take-private merger agreement at $127 per share.

  • Armstrong Parent and Armstrong Bidco

    KKR affiliates that will acquire Integer under the merger agreement.

  • KKR

    Private equity sponsor referenced via its affiliates supporting the transaction financing.

Related articles

$ITGRHighAI 9/10

What Integer's Deal Means for Minnesota's Med Device Industry

Integer Holdings, a major medical device manufacturer, is being acquired by KKR for $5.7B. Integer supplies components to companies like Abbott, Boston Scientific, and Medtronic. The deal may impact Minnesota's med-tech industry, where Integer has significant operations. KKR's acquisition could lead to consolidation in the sector, with potential implications for competition and pricing. Integer reported $1.8B in revenue last year.

$KKRHighAI 9/10

KKR to Acquire Integer Holdings in $5.7 Bn All-Cash Deal

KKR will acquire medical device outsourcing company Integer Holdings in an all-cash deal valued at about $5.7 billion, paying $127 per share and assuming Integer’s outstanding debt, according to the companies. The offer implies a 4.78% premium to Integer’s Friday close. Integer shares rose 2.4% premarket. KKR said it will expand its healthcare portfolio.

$SUPNMed

Biotech funding rises 75% year-over-year, Braveheart surges

Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.

$KKRHighAI 9/10

KKR to take Integer private for $5.7B

KKR agreed to buy Integer Holdings for about $5.7B in an all-cash deal, taking Integer private. The transaction is expected to close before year-end, subject to regulatory approvals and shareholder support. Integer stockholders would receive about $127 per share, a 51%+ premium to April 29. Integer reported $464M Q2 sales, down 2.6%.

$KKRHighAI 9/10

KKR to take Integer private in US$5.7bn deal

KKR will take Integer Holdings private in an all-cash US$5.7bn deal, paying US$127 per share plus assuming Integer’s outstanding debt. The offer is a 4.78% premium. Integer makes components for medical devices in cardiovascular and neuromodulation. KKR said the deal should close by year-end, expanding its healthcare exposure.